Nivolumab for small-cell lung cancer after platinum-based chemotherapy [ID1126]
Discontinued
Reference number: GID-TA10158
As you are aware the Department for Health and Social Care has asked NICE to carry out an appraisal of nivolumab for treating small-cell lung cancer after platinum-based chemotherapy.
However, the company have advised that the Phase III CheckMate -331 Study did not meet its primary endpoint of Overall Survival with Opdivo versus Chemotherapy in patients with previously treated relapsed small cell lung cancer. Therefore, the timelines for this appraisal are to be confirmed whilst NICE continues to liaise with company on the next steps.
As this appraisal has been referred NICE will continue to monitor any development and will update interested parties as and when the situation changes